Abbott Laboratories (ABT) FY2012 results: revenue $19.1 billion, down 11.0% on the year
Abbott Laboratories (ABT) reported revenue of $19.1 billion for fiscal 2012, the year ended 31 December 2012, down 11.0% on the year before. Net income was $6.0 billion, up 26.1%, and diluted earnings per share $3.72. The figures are the company's own, from the 10-K it filed with the SEC on 15 February 2013.
Revenue
$19.1 billion
-11.0% on the year
FY2007FY2012
Operating margin
7.1%
7.6% a year earlier
FY2007FY2012
Net income
$6.0 billion
+26.1% on the year
FY2007FY2012
Diluted EPS
$3.72
+23.6% on the year
FY2007FY2012
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Revenue
19,050
21,407
35,167
-11.0%
Cost of revenue
8,899
10,017
14,665
-11.2%
Gross profit
10,151
11,390
20,502
-10.9%
Gross margin
53.3%
53.2%
58.3%
Research and development
1,461
1,512
3,724
-3.4%
Selling, general and administrative
6,735
7,365
10,376
-8.6%
Operating income
1,360
1,629
6,088
-16.5%
Operating margin
7.1%
7.6%
17.3%
Interest expense
320
359
553
-10.9%
Pre-tax income
-220
1,236
5,713
Income tax
-457
110
1,087
Effective tax rate
n/a
8.9%
19.0%
Net income
5,963
4,728
4,626
+26.1%
Net margin
31.3%
22.1%
13.2%
Diluted EPS
$3.72
$3.01
$2.96
+23.6%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Operating cash flow
9,314
8,970
8,736
+3.8%
Capital expenditure
1,795
1,492
1,015
+20.4%
Free cash flow
7,519
7,478
7,721
+0.5%
Free cash flow margin
39.5%
34.9%
22.0%
Cash from investing
-5,560
661
-12,188
Cash from financing
195
-6,423
-1,088
Depreciation and amortisation
2,783
3,044
2,624
-8.6%
Share-based compensation
433
383
387
+13.2%
Buybacks
2,364
77.0
867
+2,970.2%
Dividends paid
3,183
2,938
2,671
+8.3%
Dividend per share
n/a
$1.92
$1.76
Diluted shares, weighted
1,592m
1,567m
1,556m
+1.6%
Balance sheet
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Shareholders' equity
26,721
24,440
22,677
+9.3%
Non-controlling interest
92.0
86.3
88.3
+6.6%
Debt
20,476
15,415
18,918
+32.8%
Other liabilities
19,946
20,336
18,890
-1.9%
Total liabilities and equity
67,235
60,277
60,574
+11.5%
Fixed assets
8,063
7,874
7,971
+2.4%
Goodwill
15,774
15,705
15,930
+0.4%
Intangible assets
8,588
9,990
12,152
-14.0%
Investments
4,645
1,663
2,105
+179.4%
Cash and equivalents
10,802
6,813
3,648
+58.6%
Receivables
7,613
7,684
7,184
-0.9%
Inventory
3,792
3,284
3,189
+15.5%
Other assets
7,957
7,264
8,395
+9.5%
Total assets
67,235
60,277
60,574
+11.5%
10-K for the year ended 31 December 2012, filed 15 February 2013: the filing.